Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Sell
44
MNMD Quote, Financials, Valuation and Earnings
Last price:
$6.30
Seasonality move
:
-10.11%
Day range:
$6.25 - $6.46
52-week range:
$4.70 - $10.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.99x
Volume:
478.1K
Avg. volume:
1.2M
1-year change:
-30.23%
Market cap:
$480.5M
Revenue:
--
EPS (TTM):
-$2.08
Analysts' Opinion
-
Consensus RatingMind Medicine has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $24.50, Mind Medicine has an estimated upside of 285.22% from its current price of $6.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $6.30.
Fair Value
-
According to the consensus of 7 analysts, Mind Medicine has 285.22% upside to fair value with a price target of $24.50 per share.
MNMD vs. S&P 500
-
Over the past 5 trading days, Mind Medicine has overperformed the S&P 500 by 9.26% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Mind Medicine does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mind Medicine has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Mind Medicine reported revenues of --.
Earnings Growth
-
Mind Medicine has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Mind Medicine reported earnings per share of -$0.41.
Enterprise value:
228.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.89x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $11B | $11.4B | -- | $3.1B | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$66.3M | -$93.9M | -$103.9M | -$22.2M | -$32.5M | |
| EBITDA | -$63.2M | -$91.7M | -$105.9M | -$22.6M | -$34.1M | |
| Diluted EPS | -$1.84 | -$2.45 | -$2.08 | -$0.59 | -$0.41 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $81.5M | $137.2M | $146.1M | $103.9M | $281.6M | |
| Total Assets | $81.5M | $164M | $170M | $124.5M | $302.2M | |
| Current Liabilities | $3M | $10.4M | $17.9M | $32.2M | $38.8M | |
| Total Liabilities | $5.7M | $12.3M | $19.1M | $46.4M | $60.7M | |
| Total Equity | $75.9M | $151.7M | $150.9M | $78.1M | $241.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$50.1M | -$64.4M | -$79.1M | -$20.6M | -$25.4M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $59.1M | $21.8M | $253.2M | $2.6M | $3.8M | |
| Free Cash Flow | -$50.1M | -$64.4M | -$79.1M | -$20.6M | -$25.4M | |
MNMD
Sector
Market Cap
$480.5M
$34.4M
Price % of 52-Week High
60.94%
44.25%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-25.35%
-39.44%
Beta (5-Year)
2.387
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.08
200-day SMA
Sell
Level
$6.86
Bollinger Bands (100)
Sell
Level
5.97 - 7.79
Chaikin Money Flow
Sell
Level
-372.9M
20-day SMA
Buy
Level
$5.72
Relative Strength Index (RSI14)
Buy
Level
54.33
ADX Line
Buy
Level
16.55
Williams %R
Sell
Level
-4.5922
50-day SMA
Sell
Level
$6.33
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
61.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Stock Forecast FAQ
In the current month, MNMD has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MNMD average analyst price target in the past 3 months is $24.50.
-
Where Will Mind Medicine Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mind Medicine share price will rise to $24.50 per share over the next 12 months.
-
What Do Analysts Say About Mind Medicine?
Analysts are divided on their view about Mind Medicine share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mind Medicine is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Mind Medicine's Price Target?
The price target for Mind Medicine over the next 1-year time period is forecast to be $24.50 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MNMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mind Medicine is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MNMD?
You can purchase shares of Mind Medicine via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mind Medicine shares.
-
What Is The Mind Medicine Share Price Today?
Mind Medicine was last trading at $6.30 per share. This represents the most recent stock quote for Mind Medicine. Yesterday, Mind Medicine closed at $6.30 per share.
-
How To Buy Mind Medicine Stock Online?
In order to purchase Mind Medicine stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is up 23.1% over the past day.
Sell
35
RGC alert for Apr 30
Regencell Bioscience Holdings [RGC] is down 11.18% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 14.88% over the past day.
